Cleared Traditional

K092274 - RANDOX BENZODIAZEPINE ASSAY

K092274 is the FDA 510(k) clearance for RANDOX BENZODIAZEPINE ASSAY by Randox Laboratories, Ltd.. It is a Class 2 Toxicology device (product code JXM) cleared through the Traditional 510(k) pathway after a 444-day FDA review.

K092274 · Randox Laboratories, Ltd. · Toxicology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Oct 2010
Decision
444d
Days
Class 2
Risk

K092274 is an FDA 510(k) clearance for the RANDOX BENZODIAZEPINE ASSAY. Classified as Enzyme Immunoassay, Benzodiazepine (product code JXM), Class II - Special Controls.

Submitted by Randox Laboratories, Ltd. (Crumlin, GB). The FDA issued a Cleared decision on October 15, 2010 after a review of 444 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3170 - the FDA toxicology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Toxicology submissions.

View all Randox Laboratories, Ltd. devices

Submission Details

510(k) Number K092274 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 28, 2009
Decision Date October 15, 2010
Days to Decision 444 days
Submission Type Traditional
Review Panel Toxicology (TX)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
357d slower than avg
Panel avg: 87d · This submission: 444d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code JXM Enzyme Immunoassay, Benzodiazepine
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3170
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.

Regulatory Peers - JXM Enzyme Immunoassay, Benzodiazepine

All 67
Devices cleared under the same product code (JXM) and FDA review panel - the closest regulatory comparables to K092274.
Healgen Multi-Drug Urine Test Cup
K163704 · Healgen Scientific, LLC · Aug 2017
Healgen Multi-Drug Urine Test Cup, Healgen Multi-Drug Urine Test Dip Card
K153597 · Healgen Scientific, LLC · May 2016
Immunalysis Benzodiazepines Urine Enzyme Immunoassay, Immunalysis Multi-Drug Calibrators
K151771 · Immunalysis Corporation · Jan 2016
VITROS CHEMISTRY PRODUCTS BENZ REAGENT, CALIBRATOR KIT 26, FS CALIBRATOR 1 AND DAT PERFORMANCE VERIFIERS I, II, III, IV
K062285 · Ortho-Clinical Diagnostics, Inc. · Dec 2006
SYNCHRON SYSTEMS BEBZODIAZAPINE (EBNZ) REAGENT
K051307 · Beckman Coulter, Inc. · Jun 2005
RANDOX BENZODIAZEPINE CLASS ASSAY
K050179 · Randox Laboratories, Ltd. · May 2005